BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/19/2015 5:46:00 PM | Browse: 292 | Download: 591
Publication Name World Journal of Hepatology
Manuscript ID 13503
Country of Manuscript Source China
2014-08-26 09:02
Peer-Review Started
2014-08-26 17:19
To Make the First Decision
2014-09-28 12:27
Return for Revision
2014-09-29 15:34
2014-10-26 11:32
Second Decision
2015-01-14 08:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-01-20 16:46
Articles in Press
2015-01-20 16:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
2015-01-27 15:43
Typeset the Manuscript
2015-04-13 16:41
Publish the Manuscript Online
2015-04-19 17:46
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Review
Article Title Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Manuscript Source Invited Manuscript
All Author List Gan-Lu Deng, Shan Zeng and Hong Shen
Funding Agency and Grant Number
Funding Agency Grant Number
National Nature Science Foundation of China 30770971
National Nature Science Foundation of China 30800518
National Nature Science Foundation of China 81070362
National Nature Science Foundation of China 81172470
National Nature Science Foundation of China 81372629
key project from the Nature Science Foundation of Hunan Province 11JJ2049
key project from the Nature Science Foundation of Hunan Province, 12JJ3118
Correspondence To Hong Shen, Professor, Institute of Medical Sciences, Xiangya Hospital, Central South University, No 87, Xiangya Road, Changsha 410008, Hunan Province, China. hongshen2000@yahoo.com
Keywords Hepatocellular carcinoma; Ramucirumab; Regorafenib; Tivantinib; Molecular targeted therapy; Sorafenib; Linifanib; Erlotinib; Everolimus; Sunitinib; Brivanib
Core Tip Sorafenib is the first drug and now the only systemic treatment to prolong overall survival benefit in patients with hepatocellular carcinoma. In recent years, many molecular targeted agents have been developed and tested. This review article aims to summarize the efforts of systemic therapeutic options and explore the potential new systemic options for this disease.
Publish Date 2015-04-19 17:46
Citation Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015; 7(5): 787-798
Url http://www.wjgnet.com/1948-5182/full/v7/i5/787.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i5.787
Full Article (PDF) WJH-7-787.pdf
Full Article (Word) WJH-7-787.doc
Revised Manuscript 13503-Review.doc
Peer-review Report 13503-Peer review(s).pdf
Answering Reviewers 13503-Answering reviewers.pdf
Scientific Misconduct Check 13503-CrossCheck.jpg
Scientific Editor Work List 13503-Scientific editor work list.pdf
Conflict-of-Interest Disclosure Form 13503-Conflict-of-interest statement.pdf
Copyright License Agreement 13503-Copyright assignment.pdf